New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2012
10:00 EDTALKS, MDCO, BCEI, DKS, VAR, CBRL, ARIA, ARQLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Citigroup... Alkermes (ALKS) initiated with a Buy at Citigroup... ArQule (ARQL) initiated with a Buy at Citigroup... Bonanza Creek Energy (BCEI) initiated with a Buy at SunTrust... Dick's Sporting (DKS) initiated with a Market Perform at BMO Capital... The Medicines Co. (MDCO) initiated with a Neutral at Citigroup... Varian Medical (VAR) initiated with a Buy at Brean Capital... Cracker Barrel (CBRL) initiated with a Buy at CL King.
News For ARIA;ARQL;ALKS;MDCO;BCEI;DKS;VAR;CBRL From The Last 14 Days
Check below for free stories on ARIA;ARQL;ALKS;MDCO;BCEI;DKS;VAR;CBRL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
16:35 EDTALKSAlkermes recent pullback a buying opportunity, says Leerink
Leerink does not expect any surprises when Alkermes reports Q1 results and views the recent pullback in shares as a buying opportunity. The firm reiterates an Outperform rating on the stock with a $66 price target.
09:59 EDTMDCOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:55 EDTCBRLCracker Barrel to host special shareholder meeting
Subscribe for More Information
07:17 EDTMDCOThe Medicines Co. downgraded to Market Perform from Outperform at Leerink
Subscribe for More Information
April 15, 2014
07:22 EDTBCEIGlobal Hunter Securities to hold a conference
1:1 Dallas Energy Day is being held in Dallas on April 15.
April 14, 2014
11:05 EDTCBRLCracker Barrel says proxy advisors recommend voting against Biglari proposals
Earlier today, Cracker Barrel Old Country Store announced that Institutional Shareholder Services, ISS, Glass, Lewis and Egan-Jones Proxy Services have unanimously recommended that Cracker Barrel shareholders vote AGAINST the non-binding advisory proposals publicly made by Biglari Capital and its affiliates requesting Cracker Barrel’s Board to immediately pursue all potential extraordinary transactions, including the sale of the company, and take any action necessary to amend the Tennessee Business Corporation Act to permit Biglari Capital to engage in an extraordinary transaction with the company. In recommending shareholders vote AGAINST the non-binding advisory proposals, all three advisory firms voiced their support for Cracker Barrel’s current strategy and agreed that seeking an immediate sale of the company is not in the best interests of the company's shareholders in light of current market conditions and the company's sustained strong performance. Commenting on the endorsement for the current strategy, Sandra B. Cochran, Cracker Barrel's President and CEO, stated: “We are extremely pleased that ISS, Glass Lewis and Egan-Jones continue to support our current strategy and agree with our recommendation that our shareholders vote AGAINST both of the proposals. We continue to believe that execution of the current operational and strategic plan remains the best means for creating long-term value for all of our shareholders.”
April 10, 2014
16:45 EDTVARVarian Medical settles patent dispute with University of Pittsburgh
Subscribe for More Information
10:00 EDTALKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:55 EDTALKSAlkermes upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
April 9, 2014
09:20 EDTDKSBofA/Merrill's retail analysts hold an analyst/industry conference call
Subscribe for More Information
07:49 EDTALKSAlkermes price target raised to $66 from $60 at Leerink
Subscribe for More Information
April 8, 2014
14:43 EDTALKSAlkermes price target rasied to $66 from $60 at Leerink
09:00 EDTALKSAlkermes rises 7.4%
Alkermes is up 7.4%, or $3.03, to $44.13
07:47 EDTALKSAlkermes to host conference call
Subscribe for More Information
07:04 EDTALKSAlkermes announces phase 3 'positive' results from aripiprazole lauroxil study
Alkermes announced "positive" topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale total scores at week 12, compared to placebo, which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application to the U.S. Food and Drug Administration in 3Q14. In addition to meeting the prespecified primary efficacy endpoint, the study also met the prespecified key secondary endpoint of improvement on the Clinical Global Impression-Improvement scale versus placebo at week 12. Aripiprazole lauroxil was generally well tolerated in the phase 3 study, and the safety profile of aripiprazole lauroxil was similar to that reported with oral aripiprazole. The most common adverse events in the study were insomnia, akathisia and headache. Alkermes will present data from the phase 3 study at an upcoming medical meeting and submit the results for publication in a peer-reviewed journal.
April 7, 2014
10:07 EDTARIAARIAD has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov will host a conference call with CEO Harvey Berger on April 10 at 10 am.
April 4, 2014
08:43 EDTMDCOPointState Capital reports 7.3% passive stake in The Medicines Co.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use